Treatment Outcomes of MicroPulse Trans-scleral Cyclophotocoagulation in Uncontrolled Glaucoma

NACompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

June 19, 2017

Primary Completion Date

February 15, 2020

Study Completion Date

February 15, 2020

Conditions
GlaucomaGlaucoma, Open-AngleGlaucoma, NeovascularGlaucoma and Ocular HypertensionGlaucoma EyeGlaucoma, UncompensatedGlaucoma Secondary
Interventions
DEVICE

MicroPulse® P3 Glaucoma Device (MP3)

"Laser settings will be programmed as follows: power-2000mW-2500mW (average 2000mW) of 810nm infrared diode laser set on micropulse delivery mode; micropulse on time-0.5ms; micropulse off time-1.1ms; and duty cycle (proportion of each cycle during which the laser is on)-31.33 %.~The laser probe will be applied in a continuous sliding or painting motion from 9:30 to 2:30 and from 3:30 to 8:30. The probe will be applied perpendicular to the limbus with the edge directly on the limbus at all times (fiberoptic tip at 3 mm posterior to the limbus).~The laser will be delivered over 360° for 160-320s. Treatment duration will be adjusted based on iris color and glaucoma severity (mild glaucoma: 160s, moderate glaucoma: 240s, advanced glaucoma: 240-320s)."

Trial Locations (1)

H2X 3E4

Centre Hospitalier de l'Université de Montréal (CHUM), Montreal

All Listed Sponsors
lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER

NCT03187418 - Treatment Outcomes of MicroPulse Trans-scleral Cyclophotocoagulation in Uncontrolled Glaucoma | Biotech Hunter | Biotech Hunter